Stroke is a major disorder of the central nervous system that poses a serious threat to human life and quality of life. Many stroke victims are left with long-term neurological dysfunction, which adversely affects the well-being of the individual and the broader socioeconomic impact. Currently, post-stroke brain dysfunction is a major and difficult area of treatment. Vagus nerve stimulation is a Food and Drug Administration-approved exploratory treatment option for autism, refractory depression, epilepsy, and Alzheimer's disease. It is expected to be a novel therapeutic technique for the treatment of stroke owing to its association with multiple mechanisms such as altering neurotransmitters and the plasticity of central neurons. In animal models of acute ischemic stroke, vagus nerve stimulation has been shown to reduce infarct size, reduce post-stroke neurological damage, and improve learning and memory capacity in rats with stroke by reducing the inflammatory response, regulating blood-brain barrier permeability, and promoting angiogenesis and neurogenesis. At present, vagus nerve stimulation includes both invasive and non-invasive vagus nerve stimulation. Clinical studies have found that invasive vagus nerve stimulation combined with rehabilitation therapy is effective in improving upper limb motor and cognitive abilities in stroke patients. Further clinical studies have shown that non-invasive vagus nerve stimulation, including ear/cervical vagus nerve stimulation, can stimulate vagal projections to the central nervous system similarly to invasive vagus nerve stimulation and can have the same effect. In this paper, we first describe the multiple effects of vagus nerve stimulation in stroke, and then discuss in depth its neuroprotective mechanisms in ischemic stroke. We go on to outline the results of the current major clinical applications of invasive and non-invasive vagus nerve stimulation. Finally, we provide a more comprehensive evaluation of the advantages and disadvantages of different types of vagus nerve stimulation in the treatment of cerebral ischemia and provide an outlook on the developmental trends. We believe that vagus nerve stimulation, as an effective treatment for stroke, will be widely used in clinical practice to promote the recovery of stroke patients and reduce the incidence of disability.
1 January 2022 in Oxidative Medicine and Cellular Longevity
Background. Vagus nerve stimulation therapy is proven to produce neuroprotective effects against central nervous system diseases and reduce neurological injury, having a positive effect on the recovery of neurological functions in mouse model of stroke. Objective. This study was aimed at exploring a wider time window for VNS treatment, investigating the long‐term behavioral improvement of long‐term VNS in mice after pMCAO, and exploring the antiapoptotic properties of VNS and its role in autophagy, all of which may be a permanent deficiency potential mechanism of neuroprotection in hemorrhagic stroke. Methods. Permanent focal cerebral ischemia and implantation of vagus nerve stimulator were performed through intracavitary occlusion of the right middle cerebral artery (MCA). The vagus nerve stimulation group received five times vagus nerve stimulation from 6 h after surgery for 5 days. Adhesive removal test and NSS neurological score were used to evaluate the neurological deficit of mice. TTC staining of mouse brain tissue was performed one week after surgery in order to assess the area of cerebral infarction. Additionally, frozen sections were stained with Fluoro‐Jade B to observe the apoptotic cells in the ischemic penumbra of brain tissue. Finally, Western blot was used to detect the changes in the levels of apoptosis‐related proteins such as cleaved‐caspase3 and Bcl‐2 and autophagy‐related proteins such as mTOR, Beclin‐1, and LC3‐II in brain tissue. Results. VNS can effectively reduce the behavioral score of pMCAO mice; TTC results showed that VNS could effectively reduce the infarct area after pMCAO (P < 0.05). After VNS intervention of the pMCAO group compared with the pMCAO+VNI group, the FJB‐positive cells in the VNS group were significantly decreased (P < 0.05); Western Blot analysis showed that the expression of cleaved‐caspase3 in the brain tissue of mice increased after pMCAO (P < 0.05), and the expression of Bcl‐2 decreased (P < 0.05). This change could be effectively reversed after VNS intervention (P < 0.05). Conclusion. VNS could effectively improve the behavioral performance of mice after permanent stroke in addition to significantly reducing the infarct size of the brain tissue. The mechanism may be related to the effective reduction of cell apoptosis and excessive autophagy after pMCAO by VNS.
Endovascular mechanical thrombectomy, combined with a tissue plasminogen activator (t-PA), is efficacious as a standard care for qualifying ischemic stroke patients. However, > 50% of thrombectomy patients still have poor outcomes. Manganese porphyrins, commonly known as mimics of superoxide dismutases, are potent redox-active catalytic compounds that decrease oxidative/nitrosative stress and in turn decrease inflammatory responses, mitigating therefore the secondary injury of the ischemic brain. This study investigates the effect of intracarotid MnTnBuOE-2-PyP5+ (BMX-001) administration on long-term, 28-day post-stroke recovery in a clinically relevant setting. The 90 min of transient middle cerebral artery occlusion was performed in young, aged, male, female, and spontaneous hypertension rats. All physiological parameters, including blood pressure, blood gas, glucose, and temperature, were well controlled during ischemia. Either BMX-001 or a vehicle solution was infused through the carotid artery immediately after the removal of filament, mimicking endovascular thrombectomy, and was followed by 7 days of subcutaneous injection. Neurologic deficits and infarct volume were assessed at 28 days in a blinded manner. The effects of BMX-001 on the carotid arterial wall and blood–brain barrier permeability and its interaction with t-PA were assessed in normal rats. There were no intra-group differences in physiological variables. BMX-001-treated stroke rats regained body weight earlier, performed better in behavioral tests, and had smaller brain infarct size compared to the vehicle-treated group. No vascular wall damage and blood–brain barrier permeability changes were detected after the BMX-001 infusion. There was no drug interaction between BMX-001 and t-PA. Intracarotid BMX-001 infusion was safe, and it significantly improved stroke outcomes in rats. These findings indicate that BMX-001 is a candidate drug as an adjunct treatment for thrombectomy procedure to further improve the neurologic outcomes of thrombectomy patients. This study warrants further clinical investigation of BMX-001 as a new stroke therapy.
Objective: In this study vagus nerve stimulation (VNS) was used in mouse ischemic stroke model to observe its effects on the proliferation of vascular endothelial cells and gliogenesis, and to explore the potential protective mechanism of VNS on ischemic stroke angiogenesis. Methods: 80 male C57BL/6J mice were randomly divided into four groups: A: Sham+VNS group; B: pMCAO+VNS group; C: pMCAO +VNI group D: Sham group. The behavioral changes of mice were monitored after operation. Laser speckle Doppler imager was used to detect the cerebral blood flow and blood vessel density of mice at 6 hours, 3 days, 7 days and 14 days after operation. Evans Blue method was used to measure blood-brain barrier integrity, the ratio of dry and wet weight of brain tissue was measured to measure the degree of edema in the brain tissue of mice in each group, CD31/Ki67, GFAP/Ki67, and Ibal/Ki67 were identified by immunofluorescence method to label new vascular endothelial cells and new glial cells, The expressions of angiogenic factors such as endothelial nitric oxide synthase (eNOS), brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) were detected by Elisa Kits.Results: 1. VNS treatment can effectively improve neurological deficit scores of the stroke mice after VNS treatment at 7 days, 14 days and 21 days (P<0.05); 2.Laser speckle Doppler imager showed that vascular density in pMCAO+VNS group was more obvious increased than in pMCAO+VNI group at every moment (P<0.05). 3.T Evans Blue method suggested that VNS could reduce the degree of damage to the blood-brain barrier after ischemic stroke (P<0.05) and also effectively reduce the degree of brain edema after pMCAO (P<0.05). 4. CD31/Ki67, GFAP/Ki67 and Ibal/Ki67 co-localize, suggesting that VNS can induce new blood vessels in the ischemic penumbra 5. VNS induce the up-regulation of BDNF, eNOS and VEGF protein expression in the ischemic penumbra of brain tissue after pMCAO (P<0.05).Conclusion: VNS can improve the nerve injury of ischemic stroke by regulating vascular endothelial cell regeneration and glial cell remodeling, and provide guidance for further exploration of stroke neuroprotection.